Clinical Trials on Recurrent Bladder Cancer

Total 56737 results

Five Prime Therapeutics, Inc.

No longer available

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer (FPA144)

Recurrent Bladder Cancer
Bozyaka Training and Research Hospital

Unknown

Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection

Recurrent Superficial Bladder Cancer | Distilled Water

Turkey
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Shanghai Pudong Hospital

Recruiting

An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer

Recurrent or Metastatic Bladder Cancer

China
University of Chicago
National Cancer Institute (NCI)

Recruiting

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Urethral Cancer Associated With Invasive Bladder Cancer

United States, China, Korea, Republic of
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Recurrent Non-Muscle Invasive Bladder Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Bladder Cancer | Recurrent Bladder Cancer | FGFR3 Gene Mutation

United States
National Cancer Institute (NCI)

Completed

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditions

United States
Istanbul Medeniyet University

Recruiting

The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Bladder Cancer Recurrent | Non-Invasive Bladder Urothelial Carcinoma

Turkey
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Adenocarcinoma of the Bladder | Distal... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Bladder Cancer | NMIBC | Urothelial Carcinoma Recurrent | Non-Muscle Invasive Bladder Cancer

United States
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Recurrent Bladder Cancer | Stage IV Bladder Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Recurrent Breast Cancer | Stage III Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
Istituto Clinico Humanitas

Unknown

Expression of Markers Related to Mitochondrial Functionality in Carcinoma of the Urinary Bladder: Comparative Retrospective Analysis Between Recurrent Tumors ("Non-responders") and Non-recurrent Tumors ("Responders") After Intravesical Treatment With Chemotherapy or Immunotherapy (MITOMARKER-MIM)

Bladder Cancer

Italy
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional...

Canada
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Recurrent Bladder Cancer | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral Cancer | Urethral Cancer Associated With Invasive Bladder Cancer | Localized Transitional Cell Cancer... and other conditions
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer

Recurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
University of Washington
National Cancer Institute (NCI)

Completed

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma | Recurrent Urethral Urothelial Carcinoma | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage 0a Bladder Cancer... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral Cancer

United States
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
National Cancer Institute (NCI)

Completed

Celecoxib in Treating Patients With Bladder Cancer

Recurrent Bladder Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Recurrent Ovarian Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Endometrial Carcinoma | Stage III Bladder Cancer | Cervical Squamous Cell Carcinoma | Stage IV Breast Cancer | Malignant Uterine Neoplasm | Recurrent Bladder Carcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
National Cancer Institute (NCI)

Completed

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Recurrent Bladder Carcinoma | Stage I Bladder Cancer AJCC v6 and v7 | Stage II Bladder Cancer AJCC v6 and v7 | Stage III Bladder Cancer AJCC v6 and v7

United States
Predictive Biosciences

Completed

Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer

Bladder Cancer Recurrence

United States
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditions

United States
Immatics Biotechnologies GmbH
Bristol-Myers Squibb

Recruiting

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
Roswell Park Cancer Institute
Johns Hopkins University; National Cancer Institute (NCI)

Terminated

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Recurrent Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
Ankara Training and Research Hospital

Recruiting

Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

Bladder Cancer | Superficial Bladder Cancer | Tumor Recurrence | Epirubicin Adverse Reaction

Turkey
Ankara Training and Research Hospital

Completed

In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?

Disease Progression | Bladder Cancer | Recurrent Bladder Cancer
Centre Leon Berard
GlaxoSmithKline

Recruiting

PREventing Second Cancers With DOSTARlimab (PREDOSTAR)

Recurrent Cancer | Second Cancer | Primary Cancer

France
Immatics Biotechnologies GmbH

Recruiting

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
University of California, Davis
Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Recurrent Bladder Carcinoma | Stage III Urethral Cancer | Stage IV Urethral Cancer | Urethral Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage III Bladder Urothelial Carcinoma | Recurrent Urothelial Carcinoma of... and other conditions

United States
University of Southern California
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
Ohio State University Comprehensive Cancer Center

Completed

2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IV A Bladder Cancer | Stage IV A Rectal Cancer | Stage IV B Colon Cancer | Stage IV B Rectal Cancer

United States
Association Pour La Recherche des Thérapeutiques...
Roche Pharma AG

Completed

Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma (CVH-CT02)

Recurrent Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

France, Belgium
Hospital Universitario de Fuenlabrada

Recruiting

En Bloc TURBT With Collins Loop vs Conventional TURBT (TURBT)

Bladder Cancer | Urothelial Carcinoma Recurrent | Bladder Urothelial Carcinoma | Bladder Neoplasm | Bladder Cancer Stage

Spain
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Not yet recruiting

The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer

Self Efficacy | Smoking Behaviors | Progression, Disease | Non-Muscle Invasive Bladder Cancer | Tumor Recurrence

Turkey
University of Southern California
National Cancer Institute (NCI)

Withdrawn

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Recurrent Bladder Carcinoma | Bladder Cancer Stage 0 | Bladder Cancer Stage I

United States
University of Thessaly

Unknown

Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women

Recurrent Urinary Tract Infections in Women

Clinical Trials on Recurrent Bladder Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations